Roger Stupp MD
Paul C. Bucy Professor of Neurological Surgery; Professor of Medicine (Hematology/Oncology) and Neurology, Northwestern University Feinberg School of Medicine; Co-Director, Northwestern Medicine Malnati Brain Tumor Institute; Associate Director for Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IllinoisDr. Roger Stupp is an internationally recognized neuro-oncologist and a leading authority on primary and metastatic brain cancer. He serves as Professor and Medical Director of the Malnati Brain Tumor Institute in the Department of Neurological Surgery and Division Chief of Neuro-Oncology in the Department of Neurology as well as Associate Director for Strategic Initiatives at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago.
Dr. Stupp is an active and dedicated clinical researcher. His special clinical interests include the multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers, as well as new drug development and the association of chemotherapy and radiation therapy. He is also closely involved in bringing new antiangiogenic and biological treatments to the clinic. He is part of Northwestern University’s Brain Tumor SPORE leadership, and he maintains close collaborations with its basic and translational research laboratories.
After receiving his medical degree from the University of Zürich Medical School and undergoing residencies in internal medicine and clinical immunology, Dr. Stupp completed fellowship training in medicine and hematology/oncology at the University of Chicago Hospitals and Cancer Center, Chicago, Illinois.
Disclosures
- Advisory boards: Celularity; GT Medical Technologies; DNAtrix; Northwest Biotherapeutics; several non–clinical stage biotech companies
Recent Contributions to PracticeUpdate:
- Rindopepimut With Bevacizumab for Patients With Relapsed EGFRvIII-Expressing Glioblastoma
- Changing Paradigms in the Management of Brain Metastases
- Chemotherapy Alone for Oligodendroglioma
- Second Interim Analysis From a Phase III Trial on Concurrent and Adjuvant Temozolomide for Anaplastic Glioma Without 1p/19q Codeletion
- Tumor-Treating Fields and Tumor Growth Patterns
- ESMO 2019: Recommendations From Dr. Roger Stupp
- ASCO 2019: Abstract Recommendations From Dr. Roger Stupp for CNS Malignancies
- An Overview of Virus-Based Agents for Glioma
- Clinically Relevant Biomarkers for Gliomas
- MGMT Promoter Testing for Patients With GBM